Pharmagen Inc. (PHRX) 0.0055 $PHRX
Pharmagen Recruits Frederick W. Mundt as Senior Vice President of Sales
PR Newswire - Tue May 06, 8:15AM CDT
Pharmagen, Inc. (OTCPINK: PHRX) (the "Company" or "Pharmagen"
today announced that Frederick W. Mundt has accepted the position of Senior Vice President of Sales. Frederick ("Fred" begin on May 2, 2014. Fred's addition is key to building out the Pharmagen Team. Fred brings a wealth of knowledge and experience in sales, business development and operational leadership. Highlights of Fred's experience includes: nine years with Astellas Pharmaceuticals, ten years with Ortho Biotech Inc., and most recently he served as Director, Commercial Deployment and Alignments with Quest Diagnostics.
Pharmagen appoints Boyd Relac as COO
M2 - Wed Apr 30, 5:23AM CDT
Sterile pharmaceutical company Pharmagen (Other OTC
HRX) disclosed on Tuesday the election of Boyd Relac as its chief operating officer.
Boyd Relac joins the Pharmagen Executive Team as Chief Operating Officer ("COO"
PR Newswire - Tue Apr 29, 8:00AM CDT
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen" today announced that Boyd Relac has been appointed as its Chief Operating Officer ("COO". Boyd brings with him over 20 years of experience including holding notable senior level positions with such companies as Dentsply International, Patterson Companies, Maly's Midwest and most recently L'Oreal/SalonCentric. Boyd also formed and honed his leadership skills as a U.S. Army Officer in elite airborne and special operations units. Boyd was awarded the Bronze Star Medal for meritorious service during Operation Desert Storm and earned 3 Meritorious Service Medals for leadership in command and staff positions of special operations units.
Pharmagen concludes bridge financing in aid of consolidation & capital restructuring
M2 - Wed Apr 23, 4:01AM CDT
Pharmaceutical company Pharmagen (Other OTCHRX) revealed on Tuesday the completion of its bridge financing.
Pharmagen Completes Bridge Financing to Support Consolidation and Capital Restructure Plan
PR Newswire - Tue Apr 22, 8:00AM CDT
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen" today announced that it has completed its bridge financing lead by Pharmagen's Chairman, Richard A. Wolpow and Bagel Boy Equity Group II, LLC. Completion of this round helps get Pharmagen one step closer to following through on a plan of consolidation and restructuring which was initiated in October 2013.
Jay Street Coffee Now Available At Sprouts Farmers Market Stores
PR Newswire - Tue Mar 04, 8:06AM CST
Jay Street Coffee, the latest innovation of the Brooklyn, New York based beverage company, ITO EN (North America) INC. has announced that Sprouts Farmers Market will be the first national retailer to carry the product. Sprouts is a specialty retailer of fresh, natural and organic foods at great prices. Its 170 stores offer a complete shopping experience that includes fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, baked goods, dairy products, frozen foods, natural body care and household items catering to consumers' growing interest in health and wellness.
Asset Management Company to Liquidate Piney Creek Power Plant
PR Newswire - Tue Jan 14, 10:17AM CST
Stuart B. Millner & Associates (SBMA)--an asset management company--recently signed a contract with Piney Creek Limited Partnership to liquidate the assets from the Piney Creek Power Plant in Clarion, PA. The facility originally cost approximately $182 million to build in 1991, and has undergone numerous expensive renovations since.
Pharmagen Partners with Bagel Boy Equity Group II, LLC and prepares to Launch its Industry Consolidation Strategy
PR Newswire - Tue Dec 17, 6:00AM CST
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" announces that is has executed an agreement with Bagel Boy Equity Group II, LLC, whereby its Managing Partner, Richard A. Wolpow will become Chairman of the Board of Directors and interim Chief Operating Officer ("COO". Wolpow will work closely with Pharmagen's CEO, Mackie Barch, and the rest of its executive team using the Company as the platform for deploying a roll-up consolidation plan in the hard-to-find secondary wholesale and sterile compounding market. Pharmagen's goal will be to build a fully integrated state-of-the-art distribution and supply chain that will drive revenue and EBITDA growth for shareholders.
Pharmagen Announces Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 1:37PM CST
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen" today announced financial results for the quarter ended September 30, 2013. On a consolidated basis, total revenues for the quarter ended September 30, 2013 were $1.074 mln and for the nine months ended September 30, 2013 were $3.770 mln compared to $1.781 mln for the quarter ended September 30, 2012 and $3.246 mln for the nine months ended September 30, 2012. While this is modest YTD growth, gross profit YTD more than doubled from $1.071 mln for the nine months ended September 30, 2012 to $2.404 mln for the nine months ended September 30, 2013. Furthermore, gross margins increased from 33% for the nine months ended September 30, 2012 to 64% for the nine months ended September 30, 2013, as Pharmagen Laboratories continues to expand its revenue streams and capacity.
Pharmagen Inc to participate at 19th Annual Scientific Meeting of SMSNA in New Orleans in November
M2 - Thu Nov 14, 10:04AM CST
Specialist drug company Pharmagen Inc (Other OTCHRX) said on Wednesday that it will take part at the upcoming Sexual Medicine Society North America (SMSNA) Conference in New Orleans, LA 21-23 November 2013.
Pharmagen to Attend 19th Annual Scientific Meeting of SMSNA
PR Newswire - Wed Nov 13, 7:00AM CST
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen" announces it will be participating at the upcoming Sexual Medicine Society North America (SMSNA) Conference in New Orleans, LA November 21-23, 2013. The SMSNA seeks to identify existing and emerging issues in the field of human sexual function and dysfunction, develop standards and guidelines for sexual medicine research and practice, and produce educational program(s) to bring leading-edge concepts of research, clinical practice, ethics, and politics to health care professionals interested in sexual medicine.
Merriman Capital Initiates on Pharmagen, Inc. with a Speculative Buy and a $0.13 Price Target
Thomson Reuters ONE - Thu Jun 13, 8:00AM CDT
SAN FRANCISCO - June 13, 2013 - Merriman Capital, Inc., a wholly-owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated coverage of Pharmagen, Inc. (OTCQB: PHRX) with a Speculative Buy rating and a $0.13 price target.
Pharmagen To Present At The Second Annual Marcum LLP MicroCap Conference
PR Newswire - Thu May 23, 10:13AM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" announced today that Mackie A. Barch, CEO, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel.
Pharmagen Inc announces 329% rise in revenues in Q1 2013
M2 - Thu May 16, 8:30AM CDT
Specialist drugs company Pharmagen Inc (OTC BBHRX) reported on Tuesday its revenues of USD1.72m for the quarter ended 31 March 2013.
Pharmagen Announces First Quarter 2013 Results
PR Newswire - Wed May 15, 12:53PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" today announced financial results for the quarter ended March 31, 2013. On a consolidated basis, revenues for the three months ended March 31, 2013 totaled $1.72 million as compared to the three months ended March 31, 2012, representing a 329% increase year-over-year. Adjusted for nonrecurring expenses, and depreciation and amortization, the company reported a slight profit for the quarter on an EBITDA basis. The company had one-time, non-recurring expenses of approximately $340k, and amortization and depreciation of approximately $335k, representing an operating loss of $666,0000. The companies branded multivitamin Clotamin® reported first quarter sales of approximately $500,000, representing a 1,000% increase compared to the first quarter of 2012. Gross margins for the company continue to improve, expanding from 44% in the first quarter of 2012 to 60% in the first quarter of 2013. Margin improvement is being driven primarily from increased sale
Private Investor Responds to Requests to Join Litigation Against Xumanii and Publishers of "Awesome Penny Stocks" and "Select Penny Stocks" Newsletters
GlobeNewswire - Wed May 15, 8:57AM CDT
Private citizen, George Sharp, responds to the hundreds of emails and telephone calls he has received from wounded investors seeking retribution for losses, by joining his lawsuit as additional plaintiffs. As previously announced, Mr. Sharp has launched litigation (San Diego County Division of California Superior Court Case No. 37-2013-00048310-CU-MC-CTL) for violations of California Business and Professions Codes 17529.5 (Anti-Spam), during a scheme to disseminate spam emails in order to artificially create a marketplace for the stocks of worthless companies at artificially high prices, in what is commonly known as a pump and dump scheme.
Pharmagen Laboratories Remains Industry Leader on Patient Safety
PR Newswire - Wed Apr 10, 3:16PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" is excited to announce that it has entered into an agreement to use proprietary ScanRDI technology from BioMerieux. Pharmagen Laboratories is only one of five sterile compounding companies in the United States to use ScanRDI, a cutting edge technology that reduces the method time for product sterility testing from 14 days to less than 3 hours. Utilizing solid phase cytometry in conjunction with fluorescent viability staining, ScanRDI allows for product sterility results in a matter of minutes. This is the only technology in the world that can detect contamination down to one viable microorganism without the need for growth or enrichment. While most compounding companies randomly skip-lot test, Pharmagen Laboratories tests every lot, every time. With this new, unparalleled turnaround time, Pharmagen can now produce new compounds in a matter of hours - giving the company an enormous competitive advantage in responding to an ever-changing market pl
Pharmagen Presents to North Carolina General Assembly at N.C. Bio's Legislative Breakfast
PR Newswire - Thu Apr 04, 10:52AM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" is excited to announce that it will be presenting its strategic vision on solving the nation's drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th. Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina. RTI International and Kymanox - both event sponsors - are North Carolina companies integral to implementing the Pharmagen manufacturing strategy.
Pharmagen Inc achieves 490% growth in revenues year-over-year
M2 - Tue Apr 02, 4:33AM CDT
Sterile pharmaceutical company Pharmagen Inc (OTC BBHRX) reported on Monday its net revenues of USD4.26m for the fiscal year ended 31 December 2012.
Pharmagen Announces Year-End Financial Results
PR Newswire - Mon Apr 01, 1:00PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen" today announced financial results for the fiscal year ended December 31, 2012. On a consolidated basis, net revenues for the fiscal year 2012 totaled $4.26 mln vs. 2011 of $863K, representing 490% growth year-over-year. The company had one-time, non-recurring expenses of $1.2 mln related to going public and the investments it made in building a foundation for future growth. The company spent much of 2012 building the cornerstones for a move toward profitability in 2013. This included acquiring BryceRx Laboratories, Inc., which not only grew the company's topline with prescription based revenue but also dramatically increased the company's gross profit.
Pharmagen Recruits Frederick W. Mundt as Senior Vice President of Sales
PR Newswire - Tue May 06, 8:15AM CDT
Pharmagen, Inc. (OTCPINK: PHRX) (the "Company" or "Pharmagen"
today announced that Frederick W. Mundt has accepted the position of Senior Vice President of Sales. Frederick ("Fred" begin on May 2, 2014. Fred's addition is key to building out the Pharmagen Team. Fred brings a wealth of knowledge and experience in sales, business development and operational leadership. Highlights of Fred's experience includes: nine years with Astellas Pharmaceuticals, ten years with Ortho Biotech Inc., and most recently he served as Director, Commercial Deployment and Alignments with Quest Diagnostics. Pharmagen appoints Boyd Relac as COO
M2 - Wed Apr 30, 5:23AM CDT
Sterile pharmaceutical company Pharmagen (Other OTC
HRX) disclosed on Tuesday the election of Boyd Relac as its chief operating officer. Boyd Relac joins the Pharmagen Executive Team as Chief Operating Officer ("COO"
PR Newswire - Tue Apr 29, 8:00AM CDT
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen"
today announced that Boyd Relac has been appointed as its Chief Operating Officer ("COO". Boyd brings with him over 20 years of experience including holding notable senior level positions with such companies as Dentsply International, Patterson Companies, Maly's Midwest and most recently L'Oreal/SalonCentric. Boyd also formed and honed his leadership skills as a U.S. Army Officer in elite airborne and special operations units. Boyd was awarded the Bronze Star Medal for meritorious service during Operation Desert Storm and earned 3 Meritorious Service Medals for leadership in command and staff positions of special operations units. Pharmagen concludes bridge financing in aid of consolidation & capital restructuring
M2 - Wed Apr 23, 4:01AM CDT
Pharmaceutical company Pharmagen (Other OTC
HRX) revealed on Tuesday the completion of its bridge financing. Pharmagen Completes Bridge Financing to Support Consolidation and Capital Restructure Plan
PR Newswire - Tue Apr 22, 8:00AM CDT
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen"
today announced that it has completed its bridge financing lead by Pharmagen's Chairman, Richard A. Wolpow and Bagel Boy Equity Group II, LLC. Completion of this round helps get Pharmagen one step closer to following through on a plan of consolidation and restructuring which was initiated in October 2013. Jay Street Coffee Now Available At Sprouts Farmers Market Stores
PR Newswire - Tue Mar 04, 8:06AM CST
Jay Street Coffee, the latest innovation of the Brooklyn, New York based beverage company, ITO EN (North America) INC. has announced that Sprouts Farmers Market will be the first national retailer to carry the product. Sprouts is a specialty retailer of fresh, natural and organic foods at great prices. Its 170 stores offer a complete shopping experience that includes fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, baked goods, dairy products, frozen foods, natural body care and household items catering to consumers' growing interest in health and wellness.
Asset Management Company to Liquidate Piney Creek Power Plant
PR Newswire - Tue Jan 14, 10:17AM CST
Stuart B. Millner & Associates (SBMA)--an asset management company--recently signed a contract with Piney Creek Limited Partnership to liquidate the assets from the Piney Creek Power Plant in Clarion, PA. The facility originally cost approximately $182 million to build in 1991, and has undergone numerous expensive renovations since.
Pharmagen Partners with Bagel Boy Equity Group II, LLC and prepares to Launch its Industry Consolidation Strategy
PR Newswire - Tue Dec 17, 6:00AM CST
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
announces that is has executed an agreement with Bagel Boy Equity Group II, LLC, whereby its Managing Partner, Richard A. Wolpow will become Chairman of the Board of Directors and interim Chief Operating Officer ("COO". Wolpow will work closely with Pharmagen's CEO, Mackie Barch, and the rest of its executive team using the Company as the platform for deploying a roll-up consolidation plan in the hard-to-find secondary wholesale and sterile compounding market. Pharmagen's goal will be to build a fully integrated state-of-the-art distribution and supply chain that will drive revenue and EBITDA growth for shareholders. Pharmagen Announces Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 1:37PM CST
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen"
today announced financial results for the quarter ended September 30, 2013. On a consolidated basis, total revenues for the quarter ended September 30, 2013 were $1.074 mln and for the nine months ended September 30, 2013 were $3.770 mln compared to $1.781 mln for the quarter ended September 30, 2012 and $3.246 mln for the nine months ended September 30, 2012. While this is modest YTD growth, gross profit YTD more than doubled from $1.071 mln for the nine months ended September 30, 2012 to $2.404 mln for the nine months ended September 30, 2013. Furthermore, gross margins increased from 33% for the nine months ended September 30, 2012 to 64% for the nine months ended September 30, 2013, as Pharmagen Laboratories continues to expand its revenue streams and capacity. Pharmagen Inc to participate at 19th Annual Scientific Meeting of SMSNA in New Orleans in November
M2 - Thu Nov 14, 10:04AM CST
Specialist drug company Pharmagen Inc (Other OTC
HRX) said on Wednesday that it will take part at the upcoming Sexual Medicine Society North America (SMSNA) Conference in New Orleans, LA 21-23 November 2013. Pharmagen to Attend 19th Annual Scientific Meeting of SMSNA
PR Newswire - Wed Nov 13, 7:00AM CST
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen"
announces it will be participating at the upcoming Sexual Medicine Society North America (SMSNA) Conference in New Orleans, LA November 21-23, 2013. The SMSNA seeks to identify existing and emerging issues in the field of human sexual function and dysfunction, develop standards and guidelines for sexual medicine research and practice, and produce educational program(s) to bring leading-edge concepts of research, clinical practice, ethics, and politics to health care professionals interested in sexual medicine. Merriman Capital Initiates on Pharmagen, Inc. with a Speculative Buy and a $0.13 Price Target
Thomson Reuters ONE - Thu Jun 13, 8:00AM CDT
SAN FRANCISCO - June 13, 2013 - Merriman Capital, Inc., a wholly-owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated coverage of Pharmagen, Inc. (OTCQB: PHRX) with a Speculative Buy rating and a $0.13 price target.
Pharmagen To Present At The Second Annual Marcum LLP MicroCap Conference
PR Newswire - Thu May 23, 10:13AM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
announced today that Mackie A. Barch, CEO, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Pharmagen Inc announces 329% rise in revenues in Q1 2013
M2 - Thu May 16, 8:30AM CDT
Specialist drugs company Pharmagen Inc (OTC BB
HRX) reported on Tuesday its revenues of USD1.72m for the quarter ended 31 March 2013. Pharmagen Announces First Quarter 2013 Results
PR Newswire - Wed May 15, 12:53PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
today announced financial results for the quarter ended March 31, 2013. On a consolidated basis, revenues for the three months ended March 31, 2013 totaled $1.72 million as compared to the three months ended March 31, 2012, representing a 329% increase year-over-year. Adjusted for nonrecurring expenses, and depreciation and amortization, the company reported a slight profit for the quarter on an EBITDA basis. The company had one-time, non-recurring expenses of approximately $340k, and amortization and depreciation of approximately $335k, representing an operating loss of $666,0000. The companies branded multivitamin Clotamin® reported first quarter sales of approximately $500,000, representing a 1,000% increase compared to the first quarter of 2012. Gross margins for the company continue to improve, expanding from 44% in the first quarter of 2012 to 60% in the first quarter of 2013. Margin improvement is being driven primarily from increased sale Private Investor Responds to Requests to Join Litigation Against Xumanii and Publishers of "Awesome Penny Stocks" and "Select Penny Stocks" Newsletters
GlobeNewswire - Wed May 15, 8:57AM CDT
Private citizen, George Sharp, responds to the hundreds of emails and telephone calls he has received from wounded investors seeking retribution for losses, by joining his lawsuit as additional plaintiffs. As previously announced, Mr. Sharp has launched litigation (San Diego County Division of California Superior Court Case No. 37-2013-00048310-CU-MC-CTL) for violations of California Business and Professions Codes 17529.5 (Anti-Spam), during a scheme to disseminate spam emails in order to artificially create a marketplace for the stocks of worthless companies at artificially high prices, in what is commonly known as a pump and dump scheme.
Pharmagen Laboratories Remains Industry Leader on Patient Safety
PR Newswire - Wed Apr 10, 3:16PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
is excited to announce that it has entered into an agreement to use proprietary ScanRDI technology from BioMerieux. Pharmagen Laboratories is only one of five sterile compounding companies in the United States to use ScanRDI, a cutting edge technology that reduces the method time for product sterility testing from 14 days to less than 3 hours. Utilizing solid phase cytometry in conjunction with fluorescent viability staining, ScanRDI allows for product sterility results in a matter of minutes. This is the only technology in the world that can detect contamination down to one viable microorganism without the need for growth or enrichment. While most compounding companies randomly skip-lot test, Pharmagen Laboratories tests every lot, every time. With this new, unparalleled turnaround time, Pharmagen can now produce new compounds in a matter of hours - giving the company an enormous competitive advantage in responding to an ever-changing market pl Pharmagen Presents to North Carolina General Assembly at N.C. Bio's Legislative Breakfast
PR Newswire - Thu Apr 04, 10:52AM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
is excited to announce that it will be presenting its strategic vision on solving the nation's drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th. Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina. RTI International and Kymanox - both event sponsors - are North Carolina companies integral to implementing the Pharmagen manufacturing strategy. Pharmagen Inc achieves 490% growth in revenues year-over-year
M2 - Tue Apr 02, 4:33AM CDT
Sterile pharmaceutical company Pharmagen Inc (OTC BB
HRX) reported on Monday its net revenues of USD4.26m for the fiscal year ended 31 December 2012. Pharmagen Announces Year-End Financial Results
PR Newswire - Mon Apr 01, 1:00PM CDT
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen"
today announced financial results for the fiscal year ended December 31, 2012. On a consolidated basis, net revenues for the fiscal year 2012 totaled $4.26 mln vs. 2011 of $863K, representing 490% growth year-over-year. The company had one-time, non-recurring expenses of $1.2 mln related to going public and the investments it made in building a foundation for future growth. The company spent much of 2012 building the cornerstones for a move toward profitability in 2013. This included acquiring BryceRx Laboratories, Inc., which not only grew the company's topline with prescription based revenue but also dramatically increased the company's gross profit. 
